Ji Y, Chen S, Yang K, et al. - In this prospective, multicenter, randomized, controlled, open-label clinical trial, researchers compared the effectiveness and safety of propranolol vs atenolol in infants (between age 5 and 20 weeks) with problematic infantile hemangiomas (IHs) who required systemic therapy. In total, 377 patients met the inclusion criteria and were randomized to the propranolol (190 [50.4%]) and atenolol (187 [49.6%]) groups. For at least 6 months, participants were randomly assigned to either propranolol or atenolol and they completed efficacy assessments 2 years after the initial treatment. According to findings, atenolol had comparable efficacy and fewer adverse events in the treatment of infants with problematic IHs when compared with propranolol. The results suggest that oral atenolol could be used as an alternative treatment option for IH patients who require systemic therapy.